About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 139 record(s)
Req # A-2019-001364
Adverse Reaction Reports (AERs). Report numbers: E2B_02475471, E2B_02414940.Organization: Health Canada
January 2021
Req # A-2019-001366
Adverse Reaction Report (AER). Report number: E2B_02119211.Organization: Health Canada
January 2021
Req # A-2019-001432
Adverse Reaction Reports (AERs). Report numbers: E2B_01884366, E2B_02166710, E2B_01756457,E2B_01869180, E2B_01774097, E2B_01859202, E2B_01871242, E2B_01912704, E2B_01922213 E2B_01924771.Organization: Health Canada
January 2021
Req # A-2019-001548
Adverse Reaction Report (AER). Report number: E2B_02763703.Organization: Health Canada
January 2021
Req # A-2019-001863
Adverse Reaction Report (AER) for DEXILANT. Report numbers: E2B_02819319. AERs for ENTYVIO: E2B_02862257, E2B_02839118, 000731529, 000731158, E2B_02854153. AERs for VEDOLIZUMAB: E2B_02822017, E2B_02853524, E2B_02818273, E2B_02858723, E2B_02862064…Organization: Health Canada
January 2021
Req # A-2019-001997
Adverse Reaction Reports (AERs). Report numbers: 000723590, E2B_02394614, E2B_02221418, E2B_02313629, E2B_02313836, E2B_02313846, E2B_02313847, E2B_02388681, E2B_02398777, 000719561, 000721513, 000722240, E2B_02191232, E2B_02308896, E2B_023156424.Organization: Health Canada
January 2021
Req # A-2019-002011
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-100222-959.Organization: Health Canada
January 2021
Req # A-2020-000092
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02729184, E2B_02729251, E2B_02729430, E2B_02729442, E2B_02813060, E2B_02729474, E2B_02729483, E2B_02730157, E2B_02730689, E2B_02730879, E2B_02732254, E2B_02745952,…Organization: Health Canada
January 2021
Req # A-2020-000115
Adverse Reaction Report (AER). Report number: E2B_02677382.Organization: Health Canada
January 2021
Req # A-2020-000135
Adverse Reaction Reports (AERs). Report numbers: E2B_02923798, E2B_02932860, E2B_02936877, E2B_02936939.Organization: Health Canada
January 2021